We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+88.59%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.65B
AUM Growth
+$539M
Cap. Flow
+$95.2M
Cap. Flow %
5.75%
Top 10 Hldgs %
47.9%
Holding
83
New
24
Increased
15
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$46.6M
2
TNGX icon
Tango Therapeutics
TNGX
+$28M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$27.9M
4
IMVT icon
Immunovant
IMVT
+$24.5M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.6M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$57M
2
ARVN icon
Arvinas
ARVN
+$47.5M
3
DYN icon
Dyne Therapeutics
DYN
+$21.8M
4
VSTM icon
Verastem
VSTM
+$20.9M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 90.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMRX icon
76
Immuneering
IMRX
$262M
– –
-950,000
Closed -$6.65M
JANX icon
77
CALL
Janux Therapeutics
JANX
$912M
– –
-500,000
Closed -$12.2M
KROS icon
78
Keros Therapeutics
KROS
$197M
– –
-850,000
Closed -$13.4M
LRMR icon
79
CALL
Larimar Therapeutics
LRMR
$377M
– –
-2,500,000
Closed -$8.07M
PEPG icon
80
PepGen
PEPG
$118M
– –
-750,000
Closed -$3.46M
PTGX icon
81
Protagonist Therapeutics
PTGX
$8.55B
– –
-300,000
Closed -$19.9M
SRRK icon
82
Scholar Rock
SRRK
$5.88B
– –
-175,000
Closed -$6.52M
EPRX
83
Eupraxia Pharmaceuticals
EPRX
$390M
– –
-900,000
Closed -$5.31M
1 2 3
4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2025 Portfolio in Review

As of Q4 2025, Logos Global Management held 83 positions worth $1.65B, up 48% from $1.12B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Logos Global Management deployed $95.2M of net new capital in Q4 2025, opening 24 new positions and adding to 15 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 1,750,000 shares worth $23.1M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $21.8M trimmed.

  • Logos Global Management's largest Q4 2025 buy was MoonLake Immunotherapeutics: 1,750,000 shares worth $23.1M.
  • Logos Global Management added most to Praxis Precision Medicines in Q4 2025, an estimated $46.6M increase.
  • Logos Global Management's biggest Q4 2025 reduction was Dyne Therapeutics, cutting an estimated $21.8M.
  • Logos Global Management fully exited Akero Therapeutics in Q4 2025, selling an estimated $57M.
  • Logos Global Management's ten largest holdings make up 48% of its $1.65B portfolio in Q4 2025.
  • Logos Global Management opened 24 new positions and closed 14 in Q4 2025.
  • Logos Global Management's portfolio value rose 48% quarter-over-quarter to $1.65B.

Based on Logos Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.